191 related articles for article (PubMed ID: 28716815)
1. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.
Tabernero J; Ohtsu A; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Ajani JA; Tomasek J; Safran H; Chandrawansa K; Hsu Y; Heathman M; Khan A; Ni L; Melemed AS; Gao L; Ferry D; Fuchs CS
Mol Cancer Ther; 2017 Oct; 16(10):2215-2222. PubMed ID: 28716815
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Yoon HH; Bendell JC; Braiteh FS; Firdaus I; Philip PA; Cohn AL; Lewis N; Anderson DM; Arrowsmith E; Schwartz JD; Gao L; Hsu Y; Xu Y; Ferry D; Alberts SR; Wainberg ZA
Ann Oncol; 2016 Dec; 27(12):2196-2203. PubMed ID: 27765757
[TBL] [Abstract][Full Text] [Related]
3. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.
Cohn AL; Yoshino T; Heinemann V; Obermannova R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia-Alfonso P; Portnoy DC; Van Cutsem E; Yamazaki K; Clingan PR; Polikoff J; Lonardi S; O'Brien LM; Gao L; Yang L; Ferry D; Nasroulah F; Tabernero J
Cancer Chemother Pharmacol; 2017 Sep; 80(3):599-608. PubMed ID: 28744667
[TBL] [Abstract][Full Text] [Related]
4. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X; Zhou L; Zhou C; Shen L
Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
[TBL] [Abstract][Full Text] [Related]
6. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
[TBL] [Abstract][Full Text] [Related]
7. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
[TBL] [Abstract][Full Text] [Related]
8. Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population.
Galos D; Balacescu L; Vidra R; Sur D
Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137901
[TBL] [Abstract][Full Text] [Related]
9. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
Javle M; Smyth EC; Chau I
Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
[TBL] [Abstract][Full Text] [Related]
13. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
Shitara K; Di Bartolomeo M; Mandala M; Ryu MH; Caglevic C; Olesinski T; Chung HC; Muro K; Goekkurt E; McDermott RS; Mansoor W; Wainberg ZA; Shih CS; Kobie J; Nebozhyn M; Cristescu R; Cao ZA; Loboda A; Özgüroğlu M
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37399357
[TBL] [Abstract][Full Text] [Related]
14. Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies.
Mansoor W; Roeland EJ; Chaudhry A; Liepa AM; Wei R; Knoderer H; Abada P; Chatterjee A; Klempner SJ
Oncologist; 2021 Sep; 26(9):e1538-e1547. PubMed ID: 34037286
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab.
Gil-Delgado MA; Lucidarme O; Bachet JB; Mahi N; Khayat D
Case Rep Gastroenterol; 2018; 12(2):532-539. PubMed ID: 30283289
[TBL] [Abstract][Full Text] [Related]
16. Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.
Fukuda N; Takahari D; Wakatsuki T; Osumi H; Nakayama I; Matsushima T; Ichimura T; Ogura M; Ozaka M; Suenaga M; Shinozaki E; Chin K; Yamaguchi K
Oncotarget; 2018 Mar; 9(20):15219-15227. PubMed ID: 29632638
[TBL] [Abstract][Full Text] [Related]
17. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M; Cleary JM; Shyr Y; Chao J; Uboha N; Cho M; Shields A; Pant S; Goff L; Spencer K; Kim E; Stein S; Kortmansky JS; Canosa S; Sklar J; Swisher EM; Radke M; Ivy P; Boerner S; Durecki DE; Hsu CY; LoRusso P; Lacy J
Br J Cancer; 2024 Feb; 130(3):476-482. PubMed ID: 38135713
[TBL] [Abstract][Full Text] [Related]
18. Claudin18.2 in Advanced Gastric Cancer.
Inamoto R; Takahashi N; Yamada Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136288
[TBL] [Abstract][Full Text] [Related]
19. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials.
Khan A; Khan H; Hughes GK; Ladd C; McIntire R; Gardner B; Peña AM; Schoutko A; Tuia J; Minley K; Haslam A; Prasad V; Vassar M
Cancer Med; 2024 May; 13(9):e7130. PubMed ID: 38698690
[TBL] [Abstract][Full Text] [Related]
20. Gold nanoparticles enhance antibody effect through direct cancer cell cytotoxicity by differential regulation of phagocytosis.
Fan L; Wang W; Wang Z; Zhao M
Nat Commun; 2021 Nov; 12(1):6371. PubMed ID: 34737259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
